Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]

ArriVent BioPharma, Inc. (AVBP) 
Company Research Source: Seeking Alpha
Investing Group Leader Follow Play 10min Summary ArriVent BioPharma's lead molecule, firmonertinib, targets NSCLC with EGFR Exon 20 insertion mutations and shows potential in both classical and nonstandard EGFR mutations. Firmonertinib has demonstrated superior efficacy over first-generation TKIs and can cross the blood-brain barrier, showing promise for patients with brain metastases. With a market cap of $798mn and a cash balance sufficient for over 10 quarters, ArriVent is financially stable to continue its development. Upcoming catalysts include topline data from the phase 3 FURVENT trial in 2025, making firmonertinib a molecule worth watching in the nonstandard EGFRm space. koto_feja ArriVent BioPharma, Inc. ( NASDAQ: AVBP ) is a recent IPO which is bringing a molecule known as firmonertinib, originally developed in China, to patients in the United States and globally. The lead indication is NSCLC with EGFR Exon 20 insertion mutation, where it has a phase 3 t Show less Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AVBP alerts
Opt-in for
AVBP alerts

from News Quantified
Opt-in for
AVBP alerts

from News Quantified